- Home
- VRE vs SUPN Comparison
VRE vs SUPN Comparison
Compare VRE & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRE
- SUPN
- Stock Information
- Founded
- VRE 1949
- SUPN 2005
- Country
- VRE United States
- SUPN United States
- Employees
- VRE N/A
- SUPN N/A
- Industry
- VRE Real Estate Investment Trusts
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- VRE Real Estate
- SUPN Health Care
- Exchange
- VRE Nasdaq
- SUPN Nasdaq
- Market Cap
- VRE 1.6B
- SUPN 1.7B
- IPO Year
- VRE 1994
- SUPN 2012
- Fundamental
- Price
- VRE $15.54
- SUPN $31.70
- Analyst Decision
- VRE Buy
- SUPN Hold
- Analyst Count
- VRE 4
- SUPN 2
- Target Price
- VRE $18.50
- SUPN $36.00
- AVG Volume (30 Days)
- VRE 589.3K
- SUPN 420.5K
- Earning Date
- VRE 04-23-2025
- SUPN 05-06-2025
- Dividend Yield
- VRE 1.87%
- SUPN N/A
- EPS Growth
- VRE N/A
- SUPN N/A
- EPS
- VRE N/A
- SUPN 1.11
- Revenue
- VRE $279,630,000.00
- SUPN $667,997,000.00
- Revenue This Year
- VRE $0.97
- SUPN N/A
- Revenue Next Year
- VRE $1.47
- SUPN $9.14
- P/E Ratio
- VRE N/A
- SUPN $28.49
- Revenue Growth
- VRE 3.92
- SUPN 11.82
- 52 Week Low
- VRE $13.84
- SUPN $25.53
- 52 Week High
- VRE $18.85
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- VRE 45.53
- SUPN 47.88
- Support Level
- VRE $15.50
- SUPN $29.16
- Resistance Level
- VRE $15.96
- SUPN $33.28
- Average True Range (ATR)
- VRE 0.40
- SUPN 1.19
- MACD
- VRE 0.02
- SUPN 0.02
- Stochastic Oscillator
- VRE 35.29
- SUPN 61.65
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.